Research at the Rehabilitation Clinical Trials Center

Research at the RCTC focuses on improving the lives of patients with chronic lung diseases. We have particular expertise in the physiological mechanisms limiting exercise and physical activity and how these contribute to morbidity, mortality and quality of life. In particular, we specialize in phase 2a clinical trials to identify drugs, devices and therapies to benefit physical function in patients with COPD, asthma and pulmonary hypertension.


General Enquiries: (310) 222-8200 


Open Trials 

Last Updated April 9th, 2022


The Effect of Dupilumab on Exercise Capacity in Patients with Moderate to Severe Asthma identifier NCT04203797

This study aims to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. 

Additional information is available on this study flyer, or please contact us to enroll.

Watch this video to learn more.


Rehabilitation Clinical Trials Center Research Participant Registry

Sign up for our participant registry, and we will contact you about current or future clinical trials for which you might qualify. Registry enrollment requires a 1 hour visit to our clinic, a medical history and a breathing test. The registry enrolls participants with a history of smoking, with or without a diagnosis of COPD, as well as a limited number of individuals who have never smoked (healthy controls). Please contact us to enroll.


The Immunologic, Metabolic and Extracellular Vesicle Response to Exercise in COPD

This study aims to determine the effects on metabolism and immunity of single actute bout of exercise and of completing a pulmonary rehabilitation program in COPD patients compared with age-matched controls. Exercise capacity, muscle mass, muscle strength and power, resting metabolic rate and fatty acid oxidation will also be measured.

Supported by the NIH REACT Center for rehabiliation research: 

And the Tobacco Related Disease Research Program:


Long-Haul COVID (PASC) Rehabilitation and Recovery Research Program

This study aims to identify whether the symptoms and immune system function associated with "long-haul" COVID (the post-acute sequelae of COVID, or PASC) can be improved by exercise training. Individuals who tested postive for COVID and continue to have symptoms 12-weeks or more after the initial infection are eligable. Participants will be enrolled in a 10-week personalized and supervised exercise training program. Parts of the study may be conducted via videoconference, for those suffering from extreme fatigue.

Supported by the Pulmonary Education and Research Foundation:


The Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) identifier NCT00608764

External Link:

This nationwide multicenter study aims to identify the genetics behind why some smokers get COPD and other do not. The study is still open to enrollment, but only of participants who have never smoked.


Determinants of 5-year Progression of Muscle Dysfunction and Inactivity in COPD 

This study will measure muscle oxidative capacity and physical activity in COPD patients, 5-years after a previous assessment, and generate models to predict patients who decline rapidly.

Supported by the ATS Foundation:

Beta-Blockers for the Prevention of Acute Exacerbations of COPD identifier NCT02587351

External Link:

βLOCK-COPD is a placebo controlled clinical trial that aims to examine the role of beta-blockers in COPD treatment. The study will enroll approximately 1028 patients at research centers across the United States including the Rehabilitation Clinical Trials Center at LA BioMed.


COPD Cachexia: Deciphering the Impact of Antioxidants, Iron and Mitochondrial Function Using 'Omics Approaches

This study aims to identify why some COPD patients lose muscle mass, while others maintain it. In particular it will investigate the effects of iron metabolism on mitochondrial function in skeletal muscle in COPD patients with and without unintentional weight loss.

Supported by the NIH, National Heart Lung and Blood Institute:


Wearable Sensors to Monitor Exacerbation Risk In COPD

This study, in collaboration with engineers at Caltech, aims to develop a wearable sensor to identify risk factors for actue COPD exacerbations by sampling sweat from the skin. Patients with stable COPD and hosptial in-patients with actue exacerbation of COPD are being enrolled   

Supported by the Tobacco Related Disease Research Program:


The Role of Systemic Mitochondrial Dysfunction in COPD and Cardiovascular Disease Risk

COPD patients are at greater risk for developing cardiovascular disease than smokers without COPD. This study aims identify whether impaired mitochondrial funciton, a key consumer of blood-borne lipids, contributes to the link between COPD and cardiovascular disease in the form of cornonary artery atherosclerosis.

Supported by the Tobacco Related Disease Research Program:


Why Get Involved in Clinical Research?

Improving the outlook for COPD patients requires a partnership among patients, researchers and healthcare providers. By working together we can speed the discovery of new ways to improve patients' breathing, physical activity and quality of life.

Participation in research may provide new information about your own health, and provides access to cutting-edge therapies.

Below is a list of clinical trials at our Center that are currently open to enrollment.

If you are a patient interested in participation in a clinical trial please contact us to enquire about eligibility or arrange a visit. Consultations may inculde the following:

Clearing the Air About COPD

Watch veteran newscaster and CBS Senior Contributor, Ted Koppel with his wife, Grace Anne, as they speak about COPD on the CBS Sunday Morning show (November 26, 2017):

Example Research Discoveries at RCTC

Privacy Policy

Your safety the safety of your personal information are our primary concern. Our privacy policy is available here.